Nataliya V. Uboha, MD, PhD close
Nataliya V. Uboha, MD, PhD

New Patients

Contact the Welcome Center for help choosing a new primary care doctor.

For Referring Physicians

How to refer a patient

Nataliya V. Uboha, MD, PhD Print Friendly Page

Faculty, University of Wisconsin School of Medicine and Public Health

Dr. Uboha is an assistant professor in the Department of Medicine at the University of Wisconsin School of Medicine and Public Health, Madison, WI. She specializes in gastrointestinal (GI) malignancies. 



UW Carbone Cancer Center
(608) 265-1700 | (800) 323-8942 | Map
UW Carbone Cancer Center
(608) 265-1700 | (800) 323-8942 | Map
University Hospital
(608) 263-7502 | (800) 323-8942 | Map
University Hospital
(608) 263-7502 | (800) 323-8942 | Map

UW School of Medicine and Public Health

Department of Medicine

Professional Certifications and Education

Board Certification Internal Medicine
Medical Oncology
Fellowship Smilow Cancer Hospital at Yale-New Haven Hospital, New Haven, CT
Residency Yale New Haven Hospital, New Haven, CT
Medical School Yale University School of Medicine, New Haven, CT

Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.

Her research interests are dedicated to the development of biomarker based early phase clinical trials for patients with GI cancer. Dr. Uboha has received numerous funding awards for her research and is actively engaged in developing clinical trials for patients with GI malignancies. Her background and PhD in molecular biology allows for in-depth understanding of molecular mechanisms underlying tumorigenesis and drug development.

PubMed Articles
Witt JS Kuczmarska-Haas A Lubner M Reeder SB Cho SY Minter R Weber S Ronnekleiv-Kelly S Abbott D LoConte N Mulkerin DL Lubner SJ Uboha NV Deming D Ritter MA Mohindra P Bassetti MF A Phase 1 Dose Escalation Study of Neoadjuvant SBRT Plus Elective Nodal Radiation with Concurrent Capecitabine for Resectable Pancreatic Cancer. Int J Radiat Oncol Biol Phys . 2021 Feb 1;109(2):458-463
[PubMed ID: 32942002]
Cecchini M Kortmansky JS Cui C Wei W Thumar JR Uboha NV Hafez N Lacy J Fischbach NA Sabbath KD Gomez CM Sporn JR Stein S Hochster HS A phase 1b expansion study of TAS-102 with oxaliplatin for refractory metastatic colorectal cancer. Cancer . 2020 Dec 22;
[PubMed ID: 33351187]
Dhakras P Uboha N Horner V Reinig E Matkowskyj KA Gastrointestinal cancers: current biomarkers in esophageal and gastric adenocarcinoma. Transl Gastroenterol Hepatol . 2020;5:55
[PubMed ID: 33073050]
Uboha NV Lubner SJ LoConte NK Mulkerin DL Eickhoff JC Deming DA Phase 1 dose escalation trial of TAS-102 (trifluridine/tipiracil) and temozolomide in the treatment of advanced neuroendocrine tumors. Invest New Drugs . 2020 Oct;38(5):1520-1525
[PubMed ID: 32253554]
Schwartz PB Uboha NV Weber SM Editorial About: "A Prospective, Open-Label, Multicenter Phase II Trial of Neoadjuvant Therapy Using Full-Dose Gemcitabine and S-1 Concurrent with Radiation for Resectable Pancreatic Ductal Adenocarcinoma". Ann Surg Oncol . 2019 Dec;26(13):4175-4177
[PubMed ID: 31440923]
Kratz JD Uboha NV Lubner SJ Mulkerin DL Clipson L Yi Y Yu M Matkowskyj KA LoConte NK Deming DA Metastatic Bulk Independently Predicts Outcomes for EGFR Precision Targeting in Colorectal Cancer. J Natl Compr Canc Netw . 2018 Dec;16(12):1442-1450
[PubMed ID: 30545991]
Shah MH Goldner WS Halfdanarson TR Bergsland E Berlin JD Halperin D Chan J Kulke MH Benson AB Blaszkowsky LS Eads J Engstrom PF Fanta P Giordano T He J Heslin MJ Kalemkerian GP Kandeel F Khan SA Kidwai WZ Kunz PL Kuvshinoff BW Lieu C Pillarisetty VG Saltz L Sosa JA Strosberg JR Sussman CA Trikalinos NA Uboha NA Whisenant J Wong T Yao JC Burns JL Ogba N Zuccarino-Catania G NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018. J Natl Compr Canc Netw . 2018 Jun;16(6):693-702
[PubMed ID: 29891520]
Burkard ME Deming DA Parsons BM Kenny PA Schuh MR Leal T Uboha N Lang JM Thompson MA Warren R Bauman J Mably MS Laffin J Paschal CR Lager AM Lee K Matkowskyj KA Buehler DG Rehrauer WM Kolesar J Implementation and Clinical Utility of an Integrated Academic-Community Regional Molecular Tumor Board. JCO Precis Oncol . 2017;1
[PubMed ID: 32913980]
Lubner SJ Uboha NV Deming DA Primary and acquired resistance to biologic therapies in gastrointestinal cancers. J Gastrointest Oncol . 2017 Jun;8(3):499-512
[PubMed ID: 28736637]
Uboha N Hochster HS TAS-102: a novel antimetabolite for the 21st century. Future Oncol . 2016 Jan;12(2):153-63
[PubMed ID: 26616466]
Deming D Uboha N Zafar SY Rosenberg S Bassetti M Glasgow S Borden EC Lubner S Adjuvant Chemotherapy for Stage II Rectal Cancer. Semin Oncol . 2015 Dec;42(6):e99-107
[PubMed ID: 26615141]
Uboha NV Flajolet M Nairn AC Picciotto MR A calcium- and calmodulin-dependent kinase Ialpha/microtubule affinity regulating kinase 2 signaling cascade mediates calcium-dependent neurite outgrowth. J Neurosci . 2007 Apr 18;27(16):4413-23
[PubMed ID: 17442826]
Stedman DR Uboha NV Stedman TT Nairn AC Picciotto MR Cytoplasmic localization of calcium/calmodulin-dependent protein kinase I-alpha depends on a nuclear export signal in its regulatory domain. FEBS Lett . 2004 May 21;566(1-3):275-80
[PubMed ID: 15147908]